Global Antibiotic Stewardship Biomarkers Market Overview
As per MRFR analysis, the Antibiotic Stewardship Biomarkers Market Size was estimated at 17.53 (USD Billion) in 2023. The Antibiotic Stewardship Biomarkers Market Industry is expected to grow from 19.36 (USD Billion) in 2024 to 39.68 (USD Billion) by 2032. The Market CAGR (growth rate) is expected to be around 8.30% during the forecast period (2024 - 2032).
Key Antibiotic Stewardship Biomarkers Market Trends Highlighted
The growing awareness of the threat posed by antibiotic resistance is driving the demand for innovative solutions, including antibiotic stewardship biomarkers. These biomarkers can assist healthcare providers in optimizing antibiotic use, reducing the risk of resistance development. The increasing prevalence of healthcare-associated infections is another key driver, as antibiotic stewardship plays a crucial role in preventing and managing these infections.
Recent trends in the antibiotic stewardship biomarkers market include the adoption of artificial intelligence and machine learning to improve the accuracy and efficiency of biomarker testing. Additionally, the development of multiplex biomarkers that can detect multiple pathogens or resistance mechanisms is gaining traction.
Opportunities for growth in the market lie in the development of biomarkers that can guide antibiotic selection for specific patient populations and in resource-limited settings. Furthermore, the integration of antibiotic stewardship biomarkers into electronic health records and decision support systems offers significant potential for improving clinical outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Antibiotic Stewardship Biomarkers Market Drivers
Rising Prevalence of Antibiotic Resistance
One of the major driving forces for the Global Antibiotic Stewardship Biomarkers Market is the increasing prevalence of antibiotic resistance. The reason for this is the fact that as bacteria become more resistant to traditional antibiotics, the demand for novel ways to detect and treat these infections will continue to rise.
As a result, antibiotic stewardship biomarkers provide insight to clinicians to properly determine whether a certain patient is likely to resist a specific type of antibiotics. As such, these biomarkers can be used to ensure that antibiotics are used in proper and adequate quantities, thus ensuring that the risk of the further development of resistance remains low.
Growing Awareness of the Importance of Antibiotic Stewardship
There is a growing awareness among healthcare professionals and the public about the importance of antibiotic stewardship. This awareness is being driven by several factors, including the increasing prevalence of antibiotic resistance, the rising cost of healthcare, and the emergence of new antibiotic stewardship guidelines. As a result of this growing awareness, there is a growing demand for antibiotic stewardship biomarkers that can help to improve antibiotic use practices.
Technological Advancements in Antibiotic Stewardship Biomarkers
Technological advancements are also playing a major role in the growth of the Global Antibiotic Stewardship Biomarkers Market. These advancements include the development of new molecular diagnostic tests, the miniaturization of diagnostic devices, and the increasing use of artificial intelligence. These advancements are making it easier and more cost-effective to identify antibiotic resistance and to develop new antibiotic stewardship biomarkers.
Antibiotic Stewardship Biomarkers Market Segment Insights
Antibiotic Stewardship Biomarkers Market Biomarker Type Insights
The global antibiotic stewardship biomarkers market segmentation by biomarker type comprises molecular biomarkers, microbiological biomarkers, host response biomarkers, pharmacokinetic/pharmacodynamic biomarkers, and imaging biomarkers.
Among these, molecular biomarkers held the largest revenue share in 2023, and it is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the increasing adoption of molecular diagnostic techniques, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), for the identification and characterization of antibiotic-resistant bacteria.
Microbiological biomarkers are expected to witness a significant growth rate during the forecast period. These biomarkers provide information about the presence and quantity of specific microorganisms, including bacteria, viruses, and fungi, in a sample. The growing demand for rapid and accurate diagnostic tests for infectious diseases is driving the growth of this segment.
Host response biomarkers, which measure the host's immune response to infection, are also expected to experience a healthy growth rate. These biomarkers can help identify patients who are at high risk of developing antibiotic resistance and guide treatment decisions.
Pharmacokinetic/pharmacodynamic biomarkers, which assess the relationship between drug exposure and efficacy, are expected to play a crucial role in optimizing antibiotic therapy. These biomarkers can help determine the optimal dosage and duration of antibiotic treatment, thereby reducing the risk of resistance development.
Imaging biomarkers, which utilize medical imaging techniques to visualize and quantify infection, are expected to gain traction in the coming years. These biomarkers can provide valuable information about the location, extent, and severity of infection, aiding in the selection of appropriate antibiotics and monitoring treatment response.
The growth of the global antibiotic stewardship biomarkers market is being driven by several factors, including the rising prevalence of antibiotic resistance, the increasing demand for personalized medicine, and the technological advancements in biomarker discovery and validation. The market is expected to continue to expand in the coming years, with a growing number of healthcare providers and researchers recognizing the importance of biomarkers in improving antibiotic stewardship practices.
Global Antibiotic Stewardship Biomarkers Market, by Biomarker Type 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Antibiotic Stewardship Biomarkers Market Application Insights
The global antibiotic stewardship biomarkers market segmentation by application includes diagnosis of bacterial infections, prediction of antibiotic resistance, optimization of antibiotic therapy, monitoring of antibiotic exposure, evaluation of new antibiotic therapies.
Among these, the diagnosis of bacterial infections segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This is primarily due to the increasing prevalence of bacterial infections and the need for rapid and accurate diagnosis to guide appropriate antibiotic therapy.
The prediction of antibiotic resistance segment is also expected to witness significant growth during the forecast period, driven by the rising concerns about antimicrobial resistance and the need for tools to predict and prevent the development and spread of resistant bacteria.
The optimization of antibiotic therapy segment is expected to grow at a moderate pace, driven by the increasing focus on improving antibiotic stewardship practices and reducing the risk of antibiotic-associated adverse events.
The monitoring of antibiotic exposure segment is expected to witness a steady growth rate, driven by the need to monitor antibiotic usage and identify patients at risk of antibiotic overuse or toxicity. The evaluation of new antibiotic therapies segment is expected to grow at a rapid pace, driven by the development and commercialization of new antibiotics and the need to evaluate their efficacy and safety.
Antibiotic Stewardship Biomarkers Market Indication Insights
The global antibiotic stewardship biomarkers market is segmented based on indication into urinary tract infections, pneumonia, sepsis, meningitis, and infective endocarditis. Among these, the urinary tract infections segment is expected to hold the largest market share in 2023, owing to the high prevalence of urinary tract infections (UTIs) worldwide. UTIs are caused by bacteria that enter the urethra and travel up the urinary tract to the bladder. Symptoms of UTIs include pain, burning, and urgency during urination, as well as cloudy or foul-smelling urine.
Pneumonia is expected to witness the highest growth rate during the forecast period, due to the increasing incidence of pneumonia, particularly in developing countries. Pneumonia is an infection of the lungs that can be caused by bacteria, viruses, or fungi. Symptoms of pneumonia include fever, chills, cough, shortness of breath, and chest pain.
The sepsis segment is also expected to grow at a significant rate during the forecast period, due to the rising prevalence of sepsis, which is a life-threatening condition that occurs when the body's response to an infection damages its own tissues and organs. Symptoms of sepsis include fever, chills, rapid heart rate, and difficulty breathing.
Antibiotic Stewardship Biomarkers Market Technology Insights
The global antibiotic stewardship biomarkers market is segmented by technology into polymerase chain reaction (PCR), next-generation sequencing (NGS), mass spectrometry, immunoassays, and biosensors. The polymerase chain reaction (PCR) segment held the largest share of the market in 2023 and is expected to continue to dominate the market throughout the forecast period.
The next-generation sequencing (NGS) segment is expected to grow at the highest CAGR during the forecast period. The mass spectrometry segment is expected to account for a significant share of the market in 2024.
The immunoassays segment is expected to grow steadily during the forecast period. The biosensors segment is expected to account for a small share of the market in 2024. The growth of the global antibiotic stewardship biomarkers market is driven by the increasing prevalence of antibiotic resistance, the rising demand for rapid and accurate diagnostic tests, and the growing adoption of personalized medicine.
Antibiotic Stewardship Biomarkers Market Regional Insights
The global antibiotic stewardship biomarkers market is segmented into regions, including North America, Europe, APAC, South America, and MEA. North America is the dominant region in the global market. The region has a well-established healthcare system and a high prevalence of antibiotic resistance.
Europe is the second largest market for antibiotic stewardship biomarkers. The region has a large population and a high burden of infectious diseases. APAC is the fastest growing region in the global market. The region has a rapidly growing population and a rising incidence of antibiotic resistance.
South America and MEA are relatively small markets for antibiotic stewardship biomarkers, but they are expected to grow at a steady pace in the coming years. The market growth is driven by increasing awareness, rising demand of products, and adoption of new technologies.
Global Antibiotic Stewardship Biomarkers Market, by Region 2023 & 2032 (USD Billion)
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Antibiotic Stewardship Biomarkers Market Key Players and Competitive Insights
Major players in the antibiotic stewardship biomarkers market are actively involved in strategic collaborations, acquisitions, and partnerships to expand their market reach and strengthen their position. For instance, in 2021, Accelerate Diagnostics, Inc. and BD (Becton, Dickinson and Company) entered a strategic partnership to develop and commercialize a rapid diagnostic test for the detection of antibiotic resistance genes.
Leading market players are investing heavily in research and development activities to enhance their product offerings and develop innovative solutions. Key players are focusing on developing biomarkers that can accurately predict antibiotic efficacy and identify patients who are at high risk of developing antibiotic resistance.
This increased investment in R&D is expected to drive the Antibiotic Stewardship Biomarkers Market development and expand the range of available diagnostic tests. The competitive landscape of the Antibiotic Stewardship Biomarkers Market is expected to remain dynamic, with new entrants and established players striving to gain a competitive edge.
BioMérieux is a global leader in the field of in vitro diagnostics. The company offers a range of Antibiotic Stewardship Biomarkers Market products, including the VITEK 2 and VITEK MS systems. These systems are used to identify bacteria and determine their antibiotic susceptibility.
BioMérieux has a strong presence in both developed and emerging markets, and it is well positioned to benefit from the growing demand for Antibiotic Stewardship Biomarkers Market products. Thermo Fisher Scientific is another major player in the Antibiotic Stewardship Biomarkers Market. The company offers a range of products, including the Sensititre ARIS system. This system is used to determine the antibiotic susceptibility of bacteria, and it is used by hospitals and other healthcare providers around the world. Thermo Fisher Scientific has a strong R&D pipeline, and it is expected to launch new products in the coming years.
QIAGEN is a leading provider of sample preparation and analysis technologies. The company offers a range of products for the Antibiotic Stewardship Biomarkers Market, including the QIAamp DNA Mini Kit. This kit is used to extract DNA from bacteria, and it is used by researchers and clinicians around the world. QIAGEN has a strong presence in both developed and emerging markets, and it is well-positioned to benefit from the growing demand for Antibiotic Stewardship Biomarkers Market products.
Key Companies in the Antibiotic Stewardship Biomarkers Market Include:
- BioMérieux
- BD
- Johnson & Johnson
- Accelerate Diagnostics
- Beckman Coulter
- Luminex
- Promega
- bioMérieux
- Accelerate Diagnostics
- Alere
- Cepheid
- Hain Lifescience
- Nanosphere
- Merck & Co.
- Cempra Pharmaceuticals
Antibiotic Stewardship Biomarkers Market Developments
The global antibiotic stewardship biomarkers market size was valued at USD 17.16 billion in 2023 and is projected to reach USD 35.0 billion by 2032, exhibiting a CAGR of 8.24% during the forecast period 2024-2032. This growth can be attributed to the rising prevalence of antibiotic resistance, increasing demand for personalized medicine, and technological advancements in biomarker discovery.
Key market players are focusing on developing innovative biomarker tests to improve antibiotic selection and reduce the risk of antimicrobial resistance. Recent developments in the market include the launch of novel biomarker tests, such as the Accelerate PhenoTest BC Kit by Accelerate Diagnostics, and the ongoing research on AI-powered biomarker discovery platforms. These advancements are expected to further drive market growth in the coming years.
Antibiotic Stewardship Biomarkers Market Segmentation Insights
Antibiotic Stewardship Biomarkers Market Biomarker Type Outlook
- Molecular Biomarkers
- Microbiological Biomarkers
- Host Response Biomarkers
- Pharmacokinetic/Pharmacodynamic Biomarkers
- Imaging Biomarkers
Antibiotic Stewardship Biomarkers Market Application Outlook
- Diagnosis of Bacterial Infections
- Prediction of Antibiotic Resistance
- Optimization of Antibiotic Therapy
- Monitoring of Antibiotic Exposure
- Evaluation of New Antibiotic Therapies
Antibiotic Stewardship Biomarkers Market Indication Outlook
- Urinary Tract Infections
- Pneumonia
- Sepsis
- Meningitis
- Infective Endocarditis
Antibiotic Stewardship Biomarkers Market Technology Outlook
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Mass Spectrometry
- Immunoassays
- Biosensors
Antibiotic Stewardship Biomarkers Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2023 |
17.53(USD Billion) |
| Market Size 2024 |
19.36(USD Billion) |
| Market Size 2032 |
39.68(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
8.30% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
BioMérieux, BD, Johnson & Johnson, Accelerate Diagnostics, Beckman Coulter, Luminex, Promega, bioMérieux, Accelerate Diagnostics, Alere, Cepheid, Hain Lifescience, Nanosphere, Merck & Co., Cempra Pharmaceuticals |
| Segments Covered |
Biomarker Type, Application, Indication, Technology, Region |
| Key Market Opportunities |
Increasing antibiotic resistance Rising awareness of antibiotic stewardship Growing adoption of precision medicine Development of novel biomarkers |
| Key Market Dynamics |
Growing antimicrobial resistance Rising demand for precision medicine Advancements in diagnostic technologies Increasing focus on healthcare associated infections Government initiatives to promote antibiotic stewardship |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The global antibiotic stewardship biomarkers market reached USD 17.53 billion in 2023.
The global antibiotic stewardship biomarkers market is expected to grow at a CAGR of 8.30% from 2023 to 2032.
North America is expected to hold the largest market share in the global antibiotic stewardship biomarkers market in 2023.
Key applications of antibiotic stewardship biomarkers include optimizing antibiotic use, reducing antibiotic resistance, and improving patient outcomes.
Key competitors in the Global Antibiotic Stewardship Biomarkers Market include bioMérieux, BD, Cepheid, Accelerate Diagnostics, and Alere.
Factors driving the growth of the global antibiotic stewardship biomarkers market include the rising prevalence of antibiotic resistance, increasing demand for personalized medicine, and government initiatives to promote antibiotic stewardship.
Challenges faced by the global antibiotic stewardship biomarkers market include the high cost of biomarker development, the need for regulatory approval, and the lack of standardized guidelines for biomarker use.
The global antibiotic stewardship biomarkers market is expected to reach USD 35.0 billion by 2032.
The hospital segment is anticipated to hold the largest market share in the global antibiotic stewardship biomarkers market in 2032.
Emerging trends in the global antibiotic stewardship biomarkers market include the development of multiplex biomarkers, the use of machine learning for biomarker discovery, and the integration of biomarkers into electronic health records.
